They received sofousbuvir and either a dose of
ribavirin based on weight or a low-dose
ribavirin. From that group, 17 patients had no detectable levels of the virus 24 weeks after treatment stopped. Of the 22 volunteers who received the low-dose ribavirin, 12 were considered cured after the end of treatment.
In an NIH press release, researcher Dr. Shyam Kottilil summed up the findings, saying, “We saw an overall cure rate of about 70% using regimens that did not include interferon.